More TRIPS PLUS

Thanks to IP-Watch for details of the US-Russia bilateral trade agreement, which seems to require measures introduced in excess of those required by TRIPS. Early data disclosure, to facilitate manufacture of generics, is under particular attack - which may well have public health and human rights implications. Another reminder that reviews of Doha, and workshops to help explore its opportunities (see http://www.wto.org/english/news_e/news06_e/trips_wp_27nov06_e.htm) are, in themselves, potentially rather pointless.